Aptose Biosciences Inc. Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Aug 8, 2024 · CIK: 882361
Sentiment: neutral
Topics: financial-reporting, operations-update
TL;DR
Aptose Biosciences filed an 8-K on Aug 8, 2024, detailing financials and operations.
AI Summary
Aptose Biosciences Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
Why It Matters
This filing provides an update on Aptose Biosciences' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing providing financial and operational updates, not indicating immediate significant risk.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- August 8, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Aptose Biosciences Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filed?
This 8-K was filed on August 8, 2024.
What were Aptose Biosciences Inc.'s former names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
What is Aptose Biosciences Inc.'s Standard Industrial Classification code?
Aptose Biosciences Inc.'s Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Where is Aptose Biosciences Inc. headquartered?
Aptose Biosciences Inc. is headquartered in Toronto, Canada.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-08-08 17:15:13
Filing Documents
- f8k_080824.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 78KB
- 0001171843-24-004614.txt ( ) — 298KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_080824_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 8, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated August 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: August 8, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer